secwatch.observer — SEC 8-K summary
======================================

Issuer:     Intellia Therapeutics, Inc. (NTLA)
CIK:        0001652130
Form:       8-K
Filed at:   2026-05-11T23:59:59+00:00
Accession:  0001193125-26-215721
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Intellia Q1 loss narrows; Phase 3 HAE data positive, rolling BLA initiated
--------------------------------------------------------------------------

- Net loss $96.2M vs $114.3M YoY; revenue $15.0M (down from $16.6M).
- Phase 3 HAELO topline: lonvo-z reduced HAE attacks 87% vs placebo (p<0.0001); mean monthly attack rate 0.26 vs 2.10.
- Rolling BLA for lonvo-z initiated; completion H2 2026 for potential US launch H1 2027.
- Cash $517.2M at Mar 31; April offering raised ~$207M gross; runway into 2028 excluding lonvo-z revenue.
- FDA lifted clinical holds on nex-z Phase 3 trials (MAGNITUDE/MAGNITUDE-2); patient screening resumed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/0001193125-26-215721-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1652130/000119312526215721/ntla-20260511.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-215721

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer